With its NDA for Thelin hung up at the FDA, Encysive saw its stock price slip after Gilead announced that the agency had accepted its application for a competing pulmonary arterial hypertension drug, ambrisentan. The FDA is giving ambrisentan a priority review. Analysts criticized Encysive for losing its lead over ambrisentan. Thelin has been approved in Europe but its FDA application has been delayed a by year.
- here's the AP report on the competition